2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo group
2017
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack
Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation 2017, 135: 1882-1893. PMID: 28246237, PMCID: PMC5511545, DOI: 10.1161/circulationaha.116.024863.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeType 1 myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeInsulin resistanceIschemic attackIschemic strokeDiabetes mellitusSerum troponinAcute coronary syndrome episodeMean age 63 yearsAcute coronary syndrome eventIndependent clinical events committeeType 2 myocardial infarctionIRIS participantsImpact of pioglitazoneRecent cerebrovascular eventsRecent ischemic strokeClinical events committeeAge 63 yearsEffect of pioglitazoneSmall myocardial infarctionCoronary artery diseaseST-segment elevation
2004
Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, Foody JM. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63: 208-213. PMID: 15277610, DOI: 10.1212/01.wnl.0000130360.21618.d0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAnimalsBrainChronic DiseaseDouble-Blind MethodDrug Evaluation, PreclinicalEndothelium, VascularFibrinolysisHemostasisHumansInflammationMiddle AgedNerve RegenerationRandomized Controlled Trials as TopicRatsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemSecondary PreventionStrokeTreatment OutcomeConceptsRenin angiotensin aldosterone systemRAAS modulationRecurrent strokeAldosterone systemCerebrovascular eventsStroke preventionSecondary preventionACE inhibitorsCerebrovascular diseaseAngiotensin II type 1 receptor blocker therapiesBlood pressure-independent mechanismsMajor public health concernReceptor blocker therapyRecurrent cerebrovascular eventsRecurrent stroke preventionAngiotensin aldosterone systemBlood pressure reductionSecondary stroke preventionRecurrent cardiac eventsPressure-independent mechanismsVascular structural changesOngoing clinical trialsNew treatment strategiesPublic health concernBlocker therapy